Recent Informatics Report Reveals 75% of Laboratory Informatics Users Listed Technology Investment and Implementation as Their Number One Priority Between 2012 and 2015

LONDON, August 30, 2012 /PRNewswire/ --

Pharma IQ has published the results of an industry-led laboratory informatics survey conducted among 6,000 pharmaceutical laboratory informatics specialists.

75% of Laboratory Informatics users listed technology investment and implementation as their number one priority between 2012 and 2015, however only 8.3% have progressed to using 'The Cloud'.

Seth Pinsky, VP of Research & Development at Abbott Labs, said: "[The] cloud hasn't helped things to be fundamentally different," while Peter Boogaard, Founder of Industrial Lab Automation, suggests, "a lack of SaaS or alternative license structures to support new customers may limit the utilisation of the current infrastructure."

Results from the survey also reveal that the implementation of laboratory informatics systems in pharmaceuticals is mature, as almost 55% of respondents implemented their major piece in the last 7-11 years, with 30% having one in place for 11 years or more.

Pharma IQ asked users what the biggest obstacles were in the day-to-day experience of laboratory informatics; 41.7% of respondents cited managing data as a challenge, as storing, sharing, archiving and retrieving data continue to be on-going concerns for researchers and scientists alike.

Stephen Rose, Solutions Architect for McLaren Applied technologies, explains, 'Instead of focusing necessarily on collecting more data and getting more data integrated into one system, making sure you're extracting the maximum value from the data you do have is a very good first step and something I'd like to see a lot more people doing."

Other reported challenges include a lack of knowledge around the standardisation of regulatory requirements, at 41.7%, integration with other non-informatics software systems and a lack of industry standards are also high on the users' agenda, at 37.5%.

This survey report was created as a part of the pre-conference research for 11th Annual ELNs & Advanced Laboratory Solutions taking place 25 - 27 September, 2012 in Milan, Italy.

The report also includes exclusive insights and case studies from:

  • Steve Thomas, Investigator at GlaxoSmithKline, who explains the  recent piece of software which was implemented to  make it easier  to drill down into data and the ability to search from almost any facet
  • Stephen Rose, Solutions Architect for McLaren Applied Technologies, reveals the data management solution McLaren built to manage and distil a huge volume of data around racing
  • Raquel Dias Miranda, Application Service Manager for Novartis, Institute for Biomedical Research, discusses their experience when integrating an ELN with a non-informatics system
  • Matthew Pustelnik, Director, Informatics at Takeda San Diego, shares his experience of integrating an informatics following the  acquisition of Syrrx

Looking towards 2015, Pharma IQ has identified some key trends to watch for between 2012 and 2015:

The integration of other Silos into existing informatics systems, a continuing growth in the outsourcing of R & D work and finally moving to an end-to-end solution that does everything from the cradle to the grave.

The full report can be viewed exclusively at Pharma-IQ.com:

http://www.pharma-iq.com/informatics/white-papers/laboratory-informatics-current-trends-predictions/


Editors Notes

About Pharma-IQ

Pharma-IQ, a division of IQPC, is an international online community focusing on providing pharmaceutical professionals with knowledge, information and articles. We are dedicated to creating a learning environment for sharing ideas, best practices and solutions within the pharmaceutical community

Pharma-IQ and IQPC provide useful training courses, conference and expositions for pharmaceutical executives to network and learn the latest pharma business development and trends occurring in organizations today. Pharma-IQ focuses on establishing an interactive experience featuring practical, objective and up-to-date insight from pharma industry leaders.

About IQPC

IQPC Ltd - IQPC has an established reputation for delivering the highest standard of industry specific conferences, seminars and internal training programmes. We aim to keep business executives up-to date with the forefront of their industries' trends, technological developments and regulatory landscape.

SOURCE IQPC

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.